Operating profit up at Novo

Thursday 5 May 2022


Novo Nordisk A/S had a robust growth in operating profit in the first quarter, even taking into account the cost of integrating the recently acquired Dicerna Pharmaceuticals Inc, a developer of candidate RNA interference (RNAi) therapeutics. Novo completed the purchase of Dicerna on 28 December 2021 and since then has been absorbing the costs.